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INTRODUCTION
Bronchiectasis is defined as permanent and abnormal dilation 
of the bronchi caused by destruction of the elastic and muscular 
components of the bronchial wall.
1 In Western countries, cystic 
fibrosis (CF) is the most common cause of bronchiectasis, and 
other causes include various respiratory infections such as 
pneumonia, pertussis, measles, and tuberculosis. In particular, 
recurrent pneumonia is the major preceding factor leading to 
bronchial damage.
2 Preexisting pneumonia is the most com-
mon cause of non-CF bronchiectasis.
3 However, with vaccina-
tion and the widespread use of antibiotics, the incidence of post-
infectious bronchiectasis has decreased. In contrast, clinicians 
are aware of the clinical implications of intrinsic defects or non-
infective extrinsic factors. These include congenital defects, irri-
tant aspiration, immunodeficiency, and mucociliary clearance 
dysfunction.
4
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High-resolution computed tomography (HRCT) is the most 
reliable noninvasive method for assessing the degree of bron-
chial wall dilatation, and thus bronchiectasis can be accurately 
diagnosed applying this technique.
5,6 Detailed investigations 
are often conducted to determine the underlying cause of bron-
chiectasis, but little point exists unless they result in a change in 
management.
In this study, we sought to ascertain the clinical features of 
bronchiectasis, a distinct change in treatment according to the 
different causes of bronchiectasis, and the distribution of bron-
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Purpose:  Bronchiectasis in children is still one of the most common causes of childhood mortality in developing countries. The aim of this study 
was to investigate the epidemiological characteristics, clinical features, underlying etiologic factors, and distinct change in the management of pa-
tients with bronchiectasis at Asan Medical Center Children’s Hospital of Seoul.  Methods:  A retrospective study of children diagnosed with bron-
chiectasis was conducted between January 1999 and December 2008. All patients underwent a comprehensive examination to identify etiologic 
factors. Data analysis in terms of age at onset, initial presenting symptoms, underlying etiology, distinct change in treatment, distribution of pulmo-
nary involvement on computed tomography (CT), and causative microbiological flora triggering secondary infections was performed.  Results:  The 
median age at the time of the diagnosis of bronchiectasis was 7.6 years (range, 2 months to 18 years). Persistent coughing was the most common 
symptom. The underlying etiologies identified in 79 patients (85.8%) included bronchiolitis obliterans (32.6%), childhood respiratory infection (20.6%), 
interstitial lung disease (17.3%), immunodeficiency (8.6%), and primary ciliary dyskinesia (4.3%). In 53 children (67%), the identified cause led to a 
distinct and individualized change in management. The distribution of CT abnormalities had no correlation with the underlying cause of bronchiecta-
sis.  Conclusions:  Selected Korean children with bronchiectasis were reviewed to identify diverse underlying etiologies. All children with bronchi-
ectasis should be comprehensively investigated because identifying underlying causes may have a major impact on their management and progno-
sis.
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chiectasis on computed tomography (CT) and causative micro-
biological flora triggering secondary infection.
MATERIALS AND METHODS
Study subjects
We enrolled 92 Korean children aged 18 years or less who were 
confirmed with bronchiectasis by chest CT (including HRCT) 
from January 1999 to December 2008. They were retrospective-
ly identified with bronchiectasis by the data warehouse system 
of Asan Medical Center Children’s Hospital based on the Inter-
national Classification of Disease-10.
Methods
The children’s medical records were retrospectively reviewed 
using a standard form. At the clinical assessment, the following 
data were included: age at symptom onset, gender, initial symp-
toms, underlying etiology, and causative microbiological flora 
triggering a secondary infection. The distribution of bronchiec-
tasis was identified in each lobe by CT scan, and widespread 
distribution was defined as the involvement of four or more 
lobes.
4 The following tests were performed to determine the 
underlying etiology of the bronchiectasis: immunological tests 
including serum immunoglobulins (Ig), complement levels, 
lymphocyte subsets, and nitroblue tetrazolium test; serum α1-
antitrypsin level; respiratory virus identification using nasopha-
ryngeal aspirates; bacterial culture of sputum; Mantoux test; 
24-hours esophageal pH monitoring; barium esophagography; 
bronchoscopic biopsy and bronchoalveolar lavage; electron 
microscopy of the nasal or bronchial mucosa cilia; sweat chlo-
ride test; and genetic studies. Each child was investigated to 
identify the underlying etiologic factor at the pediatric respirol-
ogist’s discretion, and not all children underwent all these tests.
Lung function tests were performed on 68 patients (median 
age, 8.8 years; range, 5.1–16.3 years) according to the American 
Thoracic Society. Three acceptable maneuvers were performed, 
and the best value of forced expiratory volume in the first sec-
ond (FEV1), its corresponding forced vital capacity (FVC), and 
FEV1/FVC ratio were recorded. Bronchiectasis was defined as 
idiopathic if extensive investigations failed to identify an under-
lying cause. This study was approved by the institutional review 
board of Asan Medical Center.
Statistical analysis
The demographical data and pulmonary function parameters 
were expressed as the median, range, and median percentage 
predicted, respectively.
Table 1.  Underlying etiology of bronchiectasis
Etiology No. (%) FEV1   FVC Age
Bronchiolitis obliterans 30 (33) 60 (26–84) 70 (43–100) 5.1 (0.6–11.0)
Post-infectious 28
After allogeneic HCT 2
Childhood respiratory infection 19 (21) 62 (29–100) 70 (36–99) 11.4 (0.2–16.8)
Tuberculosis 17
Cytomegalovirus 2
Interstitial lung disease 16 (17) 52 (18–132) 62 (24–119) 6.1 (2.5–13.0)
Infection 3
Previous lung injury (resolving ARDS) 2
Drug 1
Unknown 10
Idiopathic 13 (14) 73 (26–104) 84 (30–114) 9.3 (2.0–16.3)
Immunodeficiency 8 (9) 64 (49–75) 70 (54–92) 9.3 (1.1–18.0)
Primary immune defects
Panhypogammaglobulinemia 5
Hyper-IgE syndrome 1
Common variable immunodeficiency 1
Secondary immune defects
Post-chemotherapy 1
Primary ciliary dyskinesia 4 (4) 77 (67–88) 81 (74–93) 9.8 (5.7–14.1)
Cystic fibrosis 2 (2) 91 87 3.3 (0.3–6.3)
FEV1 and FVC are presented as the median percentage predicted (range); age is presented as years (range).
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; HCT, hematopoietic cell transplantation; ARDS, acute respiratory distress syndrome; Ig, 
immunoglobulin.Bronchiectasis in Children AAIR 
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RESULTS
Underlying etiology of bronchiectasis
Ninety-two patients (47 males and 45 females; male to female 
ratio, 1.04:1) participated. The median age of the patients was 
7.6 years (range, 2 months to 18 years). An etiology of bronchi-
ectasis was identified in 79 patients (86%): bronchiolitis obliter-
ans (33%, n=30), primary causative respiratory infection (21%, 
n=19), interstitial lung disease (17%, n=16), immunodeficiency 
(9%, n=8), primary ciliary dyskinesia (4%, n=4), and CF (2%, 
n=2). Of the 19 patients with respiratory infection, 17 (89.4%) 
had tuberculosis. Etiologic factors were not identified in 13 pa-
tients (14%). Among the 92 patients, 68 (74%) underwent a pul-
monary function test: median FEV1, 63%; median FVC, 71% 
(Table 1).
Tests for the diagnosis of bronchiectasis and their diagnostic 
yield are described in Table 2.
Main symptoms of bronchiectasis
At the time of the bronchiectasis diagnosis, the main symptoms 
were chronic cough (50%), repeated respiratory infection (25%), 
dyspnea (25%), recurrent wheeze (20%), fever (10%), and he-
moptysis (8%) (Table 3).
Specific treatments according to the causes of bronchiectasis
Of the 79 patients with identified etiologic factors, 53 were treat-
ed as follows according to the causes of bronchiectasis. Nineteen 
patients with bronchiolitis obliterans and eight patients with in-
terstitial lung disease were treated with regular, high-dose 
methylprednisolone pulse therapy, six patients with immuno-
deficiency were treated with immunoglobulin replacement 
therapy, two patients with interstitial lung disease were treated 
with gancyclovir for cytomegalovirus infection, and one patient 
with interstitial lung disease due to paragonimiasis was treated 
with praziquantel.
Distribution of bronchiectasis
The distribution of bronchiectasis assessed by chest CT is 
shown in Table 4. In patients with bronchiolitis obliterans, 10 of 
30 (33%) showed widespread distribution, and the most com-
mon involved sites were the lower lobes (93%). In patients with 
respiratory infection, three of 19 (15%) showed widespread dis-
tribution, and this incidence was relatively lower than patients 
with other identified etiologic factors. Most patients with im-
munodeficiency showed an even distribution, but the statisti-
Table 2.  Investigation results
Investigation
Number  
performed (%)
Number  
abnormal (%)
Bronchoscopy with alveolar lavage 59/92 (64) 8/59 (13)
Immunological workup 50/92 (54) 7/50 (14)
Electron microscopy 35/92 (38) 3/35 (8)
Mantoux test 13/92 (14) 3/13 (23)
α1-antitrypsin 30/92 (32) 0/30 (0)
Gene analysis 11/92 (12) 2/11 (18)
Sweat chloride test 2/92 (2) 1/2 (50)
Barium contrast study 4/92 (4) 2/4 (50)
Data are presented as n/N (%).
Table 3.  Symptom at the time of bronchiectasis diagnosis
Symptom Cases n (%) (n=92)
Chronic cough 46 (50)
Recurrent respiratory infection 23 (25)
Dyspnea 23 (25) 
Recurrent wheeze 18 (20)
Fever 9 (10)
Hemoptysis 7 (8)
Recurrent sinusitis 5 (5)
Abnormal simple radiograph findings 4 (4)
Weight loss 3 (3)
Exercise intolerance 3 (3)
Chest pain 3 (3)
Table 4.  Lobar involvement of bronchiectasis
UL ML LL Widespread* Unilateral
† Bilateral
‡
BO 19 15 28 10 11 19
Respiratory infection 14 4 10 3 13 6
ILD 9 9 13 6 2 14
Immunodeficiency 7 6 6 2 1 7
PCD 2 2 3 1 2 2
CF 1 0 2 1 1 1
Idiopathic 8 6 11 5 7 6
Total 60 42 73 28 37 55
Data are presented as n.
*Widespread: involvement of ≥4 lobes, 
†Unilateral: involvement only on side, 
‡Bilateral: involvement on both sides.
UL, upper lobe involvement; ML, middle lobe involvement; LL, lower lobe involvement; BO, bronchiolitis obliterans; ILD, interstitial lung disease; PCD, primary ciliary 
dyskinesia; CF, cystic fibrosis.Kim et al.
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cal significance was difficult to evaluate due to the small num-
ber of cases. Twenty-eight patients (30%) showed a widespread 
distribution, suggesting that a considerable number of patients 
with bronchiectasis may have diffuse involvement. No signifi-
cant association was observed between the distribution of 
bronchiectasis on chest CT and the causes of bronchiectasis.
Causative secondary infection microorganisms in the patients 
with bronchiectasis
The microorganisms associated with each diagnosis are shown 
in Table 5. The most common organisms were Haemophilus in-
fluenza (15%), Staphylococcus aureus (13%), Streptococcus pneu-
monia (5%), Pseudomonas aeruginosa (5%), and Mycoplasma 
pneumonia (5%). Candida parapsilosis was isolated from one 
patient with immunodeficiency (Table 5).
DISCUSSION
Bronchiectasis is a relatively frequent complication of lower 
respiratory tract infections and remains a persistent problem in 
children from developing countries.
7,8 In developed countries, 
the incidence of bronchiectasis has decreased due to improve-
ments in socioeconomic conditions and effective treatment of 
bacterial pneumonia (including the development of broad-
spectrum antibiotics).
The majority of the clinical data have indicated that bronchi-
ectasis usually occurs in preschool-age children.
9 In our study 
group, the mean onset age was 7 years and 7 months, and bron-
chiectasis occurred before 5 years of age in 39 patients (42%). 
As bronchiectasis presents no pathognomonic symptoms, iden-
tifying the etiologic factors based only on clinical symptoms 
was difficult in most cases. Other reports in the literature show 
that cough and sputum production were the most common 
symptoms,
9,10 and in this study, chronic cough was the most 
common (Table 3). Considering that bronchiectasis occurred 
in 39 children (42%) aged ≤5 years, clinicians should be aware 
of the possibility that patients with chronic cough may have 
bronchiectasis regardless of their age. Wheezing is reported to 
be the main symptom in 20% of children with bronchiectasis.
11 
Eighteen patients (20%) in our study group had recurrent wheez-
ing as a main symptom. Hemoptysis is a frequent symptom in 
adult patients with bronchiectasis, whereas it is a relatively un-
common in pediatric patients.
7 In our study group, hemoptysis 
was noted in only seven patients (8%). Clubbing of the fingers 
was present in four patients (4%). Previous studies have report-
ed that clubbing of the fingers occurs in 3–51% of patients.
7,9,10
Bronchiectatic lesions are most commonly found in the lower 
lobes, probably because mucociliary clearance is facilitated by 
gravity in the upper lobes.
7,11 In this study, bronchiectatic lesions 
were identified most commonly in the left lower lobe, followed 
by the right lower lobe and left upper lobe (Table 3). Idiopathic 
bronchiectasis occurs predominantly in the lower lobe, bron-
chiectasis due to primary ciliary dyskinesia in the middle lobe, 
and bronchiectasis due to hypogammaglobulinemia in the low-
er/middle lobe and lingual segment.
12–14 However, whether the 
distribution of bronchiectasis might be sufficiently characteris-
Table 5.  Causative secondary infection microbiological flora
BO
Respiratory 
infection
ILD Immunodeficiency PCD CF Idiopathic Total
Haemophilus influenzae 7 1 3 1 1 1 14
Staphylococcus aureus 4 1 1 1 2 3 12
Streptococcus pneumoniae 2 1 1 1 5
Mycoplasma pneumonia 3 1 1 5
Pseudomonas aeruginosa 1 1 1 2 5
Virus
Influenza 4 1 5
Parainfluenza 1 2 1 4
RSV 1 1 1 1 4
Adenovirus 3 1 2 6
CMV 3 2 1 1 2 9
EBV 2 1 3
Others Acinetobacter 
baumani (n=1), 
Klebsiella (n=1), 
Enterobacter  
cloacae (n=1)
Enterobacter 
cloacae (n=1)
Stenotrphomon-
as maltophilia 
(n=1)
Candida  
parapsilosis (n=1)
Stenotrphomon-
as maltophilia 
(n=1)
Acinetobacter 
baumani (n=1), 
Stenotrphomon-
as maltophilia 
(n=1)
Data are presented as n.
BO, bronchiolitis obliterans; ILD, interstitial lung disease; PCD, primary ciliary dyskinesia; CF, cystic fibrosis; RSV, respiratory syncytial virus; CMV, cytomegalovirus; 
EBV, Epstein–Barr virus.Bronchiectasis in Children AAIR 
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tic for a specific cause to be diagnosed is still controversial.
15,16 
In this study, as considerable overlap occurred in the distribu-
tion of bronchiectatic lesions on CT between different diseases, 
the cause of bronchiectasis could not be predicted based on the 
distribution of bronchiectatic lesions.
Comprehensive investigations are necessary to identify the 
cause of bronchiectasis in all children with bronchiectasis. Pre-
disposing factors such as immunodeficiency, CF, and chronic 
aspiration should be considered according to clinical features. 
The importance of lung damage after respiratory infections, such 
as pneumonia, pertussis, measles, and tuberculosis, as a cause 
of bronchiectasis is difficult to estimate, but is still the most com-
mon cause in developing countries.
2,8 In this study, although 40 
patients (43%) had post-infectious bronchiectasis, no predis-
posing factors were found in 21 patients with the exclusion of 
tuberculosis (n=17) and cytomegalovirus infection (n=2), and a 
considerable number of patients with bronchiolitis obliterans 
and interstitial lung disease showed such findings. The etiologi-
cal factor most commonly associated with bronchiectasis is 
childhood infection.
17 With the widespread use of antibiotics 
and early regular vaccination, the incidence of infectious diseas-
es has decreased. However, intrinsic abnormalities have been 
become more important predisposing factors. In this study, 
bronchiolitis obliterans was the most important underlying 
cause of bronchiectasis, suggesting that bronchiolitis obliterans 
due to viral or mycoplasma infections of the lower respiratory 
tract in children may induce progressive damage to the airway. 
However, as our hospital is a tertiary medical center, in which 
regional hospitals refer such patients, prospective studies are 
needed to confirm our result that bronchiolitis obliterans is the 
most common underlying etiology of childhood bronchiecta-
sis. Furthermore, interstitial lung disease accounted for 17% of 
all patients, which requires more attention in clinical settings. 
Based on the result that bronchiectasis associated with bronchi-
olitis obliterans or interstitial lung disease occupied 50% of all 
patients, patients with bronchiolitis obliterans or interstitial lung 
disease should be closely observed on long-term follow-up.
The most common form of immunodeficiency associated 
with bronchiectasis in this study was panhypogammaglobu-
linemia (Table 1). Additionally, serum IgG subclass values can 
be low in patients with bronchiectasis, even in some cases with 
a normal total IgG level.
18,19 Based on these results, IgG subclass 
levels should be measured even if total IgG is within the normal 
range.
In this study, three patients had ultrastructural abnormalities 
in the cilia on an electron microscopic examination and one had 
situs inversus. We assessed the ciliary ultrastructure of the nasal 
or bronchial mucosal membrane to diagnose primary ciliary 
dyskinesia. In patients with a normal ultrastructure of the cilia, 
primary ciliary dyskinesia can be diagnosed using low ciliary 
beat frequency.
20 Therefore, to reduce the risk of misdiagnosis 
of primary ciliary dyskinesia, an examination of the ultrastruc-
ture of the cilia along with an analysis of ciliary beat frequency 
are mandatory. In this study, as we did not analyze ciliary beat 
frequency, some cases of primary ciliary dyskinesia might have 
been underestimated in the cases of unidentified underlying 
etiology.
Prolonged presence of a foreign body within the airway can 
result in the development of bronchiectasis.
21,22 In this study, 
only four patients underwent a diagnostic workup for the pres-
ence of foreign bodies. Two patients were diagnosed with gas-
troesophageal reflux, which were excluded from the etiologic 
factors in this study due to the lack of its causal relationship with 
bronchiectasis.
Idiopathic bronchiectasis was found in 13 patients (14%). The 
incidence of idiopathic bronchiectasis in this study was lower 
than that of previous studies. Forty-eight percent of the subjects 
from a New Zealand cohort, despite extensive investigations, 
had no known underlying cause for their bronchiectasis.
23 These 
results suggest that further diagnostic investigations are neces-
sary to identify the etiologic factors and to treat bronchiectasis 
properly.
Our patients were treated by chest physical therapy and pos-
tural drainage with bronchodilator therapy, which may assist in 
mobilizing endobronchial secretions. Furthermore, short-term 
antibiotic therapy was performed to reduce the volume and 
bacterial density of sputum. Some studies have reported that 
such treatment modalities improve bronchial hyperreactivity 
and pulmonary function.
24,25 Prompt and effective antibiotic 
therapy is essential to treat acute exacerbation of infection, and 
this therapy should be prescribed on the basis of bacterial cul-
ture and sensitivity tests.
7,9 Although inflammation plays a cru-
cial role in the pathogenesis of bronchiectasis, the use of anti-
inflammatory agents has not been established. Inhaled high-
dose fluticasone is effective for reducing the sputum inflamma-
tory index in patients with bronchiectasis.
26 In a Cochrane data-
base, although inhaled steroids had no significant effect on 
treatment outcome, they significantly improved FEV1, FVC, and 
peak expiratory flow rate.
27
To prevent bronchiectasis progression, accurately identifying 
and treating the underlying disease properly is important. How-
ever, how different treatment modalities affect the natural course 
of childhood bronchiectasis has not been studied.
28 The neces-
sity for surgical treatment has decreased due to early detection 
and improved drug therapy.
2 Most studies have agreed that ag-
gressive drug therapy should be conducted before surgical treat-
ment, and some reports of effective surgical treatment have 
been published.
29,30 However, no significant difference in clini-
cal improvement between medical and surgical treatment was 
observed.
19 In our study group, no patient was treated with sur-
gery.
This study had some limitations. First, this was a cross-sec-
tional study, which could not track the progression of the radio-
logical abnormalities and disease course of bronchiectasis. Sec-Kim et al.
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ond, a possibility of referral bias existed. Some patients did not 
undergo all interventions. For example, some patients with de-
finitive evidence of panhypogammaglobulinemia did not un-
dergo further diagnostic tests. The prevalence of lung damage 
following infections seemed to be difficult to accurately estimate 
due to incorrect recall and reporting. Third, the time period be-
tween symptom onset and diagnosis was not quantified. Chest 
CTs may have been performed very late in the disease process 
when a spilling-over effect of the underlying disease may have 
occurred. For this reason, a correlation between the distribution 
of bronchiectatic lesions on chest CT scans and the etiologic fac-
tors was not determined.
In summary, the underlying causes of bronchiectasis in chil-
dren were different from those in adults. CF is a common cause 
of bronchiectasis in childhood in Western countries. Compared 
to Western countries, this study showed that cystic fibrosis was 
uncommon and that bronchiolitis obliterans was the most im-
portant etiology. Thus, long-term follow-up is needed to detect 
the development of bronchiectasis in children with bronchiolitis 
obliterans. During childhood, intrinsic factors such as immuno-
deficiency are more implicated in the causes of bronchiectasis, 
so extensive investigations are needed to ascertain early imple-
mentation of therapy. Ultimately, this study suggests that iden-
tification of underlying causes through comprehensive investi-
gation in children with bronchiectasis has a significant impact 
on their management and prognosis.
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